Porcine pseudorabies virus (PRV)-YF strain and its application

Patent metadata

Field	Value
Publication number	US-9783788-B2
Application number	US-201615011608-A
Country	US
Kind code	B2
Filing date	Jan 31, 2016
Priority date	Feb 11, 2015
Publication date	Oct 10, 2017
Grant date	Oct 10, 2017

Abstract

The present invention relates to the technical field of porcine pseudorabies virus, and more particularly to a porcine pseudorabies virus (PRV)-YF strain, with the preservation No. of CCTCC No. V201502. The present invention also provides an application of the porcine pseudorabies virus (PRV)-YF strain in preparing an inactivated vaccine of the porcine pseudorabies virus, the inactivated vaccine of the porcine pseudorabies virus and a preparation method thereof. It is proved through an immune efficacy evaluating test and a safety test that the inactivated vaccine of the porcine pseudorabies virus has good immune protective efficacy and is safe for weaned piglets, replacement gilts, pregnant sows and the like.

First claim

We claim:

1. A vaccine of porcine pseudorabies virus (PRV), comprising an adjuvant and a virus liquid containing an inactivated porcine pseudorabies virus PRV-YF strain; wherein the PRV-YF strain is isolated from tonsils and brain tissues of pathogenetic piglets; the preservation name is porcine pseudorabies virus PRV-YF strain; the preservation organization is China Center for Type Culture Collection (CCTCC); the preservation date is Jan. 21, 2015; and the preservation number is CCTCC No. V201502.

2. A preparation method for the vaccine of the porcine pseudorabies virus according to claim 1 , comprising the following steps:
1) culturing the porcine pseudorabies virus PRV-YF strain to obtain a virus liquid;
2) adding an inactivator in the virus liquid for inactivating the virus; and then, adding a terminator for terminating inactivation to obtain an inactivated virus liquid of the PRV-YF strain; and
3) preparing a water phase and an oil phase and emulsifying to obtain the vaccine of the porcine pseudorabies virus.

3. The preparation method according to claim 2 , characterized in that: the virus content of the virus liquid prepared in Step 1) is not less than 10 7.0 TCID 50 /ml.

4. The preparation method according to claim 2 , characterized in that: the inactivator described in Step 2) is pyrrole; and weighing by w/v, the pyrrole added in the virus liquid accounts for 0.1% to 1% of the total amount of the virus liquid.

5. The preparation method according to claim 2 , characterized in that: the inactivation time is 12 to 60 h; and the inactivation temperature is 37° C.

6. The preparation method according to claim 2 , characterized in that: the terminator described in Step 2) is sodium thiosulfate; and weighing by w/v, the sodium thiosulfate added in the virus liquid accounts for 0.1% to 5% of the total amount of the virus liquid.

7. The preparation method according to claim 2 , characterized in that: weighing by w/v, the sodium thiosulfate added in the virus liquid accounts for 0.5% to 5% of the total amount of the virus liquid.

8. The preparation method according to claim 2 , characterized in that: Step 3) comprises the following steps:
A. Preparation of water phase: taking the inactivated virus liquid of the PRV-YP strain prepared in Step 2) and adding the same into Span-80 with the final concentration of 0.75%, mixing while adding until Span-80 is thoroughly dissolved, thereby generating the water phase;
B. Preparation of oil phase: taking 141.75 parts of white oil, adding 7.5 parts of Span-80, fully mixing, sterilizing for 30 min at 121° C., cooling to room temperature for standby, thereby generating the oil phase;
C. Emulsifying the oil phase and the water phase by 1.5:1; adding the water phase into the oil phase slowly, shearing after homogenizing for 1-3 min, thereby generating a homogeneous emulsion.

Assignees

• Zhaoqing Dahuanong Biological Medicine Co Ltd
• Univ South China Agricult

Inventors

• Chen Ruiai
• Huang Hongliang
• Ren Changbao
• Xie Xiaoyu
• She zheng
• Zhan Xuanzi
• Deng Xiaoxiong
• Tang Manhua

Classifications

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N2710/16763

  by chemical treatment · CPC title

• C12N2710/16734

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K2039/5252

  inactivated (killed) · CPC title

• A61P31/22

  for herpes viruses · CPC title